Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2020-02-11 Board/Management Inform…
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
CEO Appointment and Establishment of US Office 5 pages 129.4KB
Board/Management Information Classification · 100% confidence The document is an ASX announcement dated 12 February 2020 regarding the appointment of a new CEO and the establishment of a US office by PYC Therapeutics. It includes detailed information about the CEO's remuneration package, employment terms, and strategic plans for the company. There are no financial statements, quarterly or annual results, or audit information presented. The content focuses on management changes and corporate governance matters related to executive appointments. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length (15,000 characters) and detailed content confirm it is not a brief announcement or a report publication notice but a substantive management announcement.
2020-02-11 English
Initial Director's Interest Notice 2 pages 94.4KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the director's relevant interests in securities, including unlisted options held by the director. There is no financial performance data, earnings information, or management discussion. The content is focused on reporting the personal share transactions or holdings of a company director. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is short and specific to director interests, confirming it is not a full report or announcement of a report but a direct insider transaction notice.
2020-02-11 English
Investor Call 27 February 2020 2 pages 90.2KB
Investor Presentation Classification · 70% confidence The document is an ASX announcement dated 5 February 2020, primarily informing about an upcoming investor call scheduled for 27 February 2020. It invites shareholders to register and submit questions for the call. The content includes company background information and forward-looking statements but does not contain any financial data, detailed financial results, or substantive analysis. The document is relatively short (3349 characters) and serves as a notice or invitation rather than a report or transcript. It does not contain the actual transcript of the call, financial statements, or detailed investor presentation materials. Therefore, it is best classified as an Investor Presentation (IP) type document, as it is a detailed presentation for investors focusing on financials, strategy, and market position, albeit in announcement form about the call. However, since it is an announcement of an investor call rather than the call transcript or a full presentation, the closest fitting category is Investor Presentation (IP) with moderate confidence.
2020-02-04 English
Expansion Of Drug Development Pipeline 3 pages 123.6KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 3 February 2020 from PYC Therapeutics. It discusses the expansion of the company's drug development pipeline with the addition of six new precision medicine programs. The content focuses on business updates related to drug development progress, partnerships, and future plans. There are no financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. The document is a corporate announcement about pipeline expansion and strategic progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. Therefore, the document fits best into the category of a Capital/Financing Update (CAP), as it relates to updates on company development activities and strategic progress that could impact capital or financing considerations.
2020-02-02 English
Appendix 4C - quarterly 4 pages 59.2KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C' and is described as a 'Quarterly report for entities subject to Listing Rule 4.7B'. It contains detailed consolidated cash flow statements for the current quarter and year-to-date periods, including operating, investing, and financing activities. It also includes estimated cash outflows for the next quarter and a compliance statement signed by the company secretary. The document is approximately 12,930 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with a comprehensive quarterly financial report rather than a simple earnings release or announcement. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q2 2019
2020-01-30 English
Quarterly Shareholder Update 3 pages 97.3KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 6 January 2020 titled 'Quarterly Shareholder Update'. It provides highlights on drug development milestones, upcoming clinical trial plans, and pipeline expansion. The content is forward-looking and strategic, focusing on progress and future plans rather than presenting actual financial statements or detailed financial data. The length is about 6106 characters, which is relatively short and more consistent with an update or announcement rather than a full financial report. There is no mention of quarterly financial results, earnings, or detailed financial analysis. The document does not fit the definition of an Interim/Quarterly Report (IR) because it lacks substantive financial data or statements. It is also not an Earnings Release (ER) since it does not announce financial results. The document is best classified as a Capital/Financing Update (CAP) because it provides an update on the company's development progress and strategic milestones relevant to investors, which is typical for capital market communications about company progress and value creation potential. Therefore, the most appropriate classification is CAP with high confidence.
2020-01-05 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.